Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Applied Biologics extends longstanding system-wide agreement with Providence Health & Services for XWRAP®.
-
Applied Biologics initiates multi-center real-world outcomes study of XWRAP® across chronic wound types.
-
Applied Biologics announces submission of XWRAP® translational research abstract to SAWC Fall 2026.
-
Applied Biologics introduces ECM Preservation Technology™ (EPT™), the proprietary manufacturing platform behind XWRAP®.
-
Applied Biologics' VA FSS contract shifts to Evergreen structure, enabling potential XWRAP® access for up to 20 years.
-
Applied Biologics submits CAMPX Trial abstract to SAWC Fall 2026, showing XWRAP improved DFU closure rates to 30.9% vs. 17.5% for standard of care alone.
-
Applied Biologics presents interim CAMPX Trial data at SAWC Spring 2026, highlighting encouraging wound closure trends for XWRAP® in diabetic foot ulcers.
-
Applied Biologics receives FDA IND clearance for BIOxHEAL, advancing its lead biologic therapy into Phase 3 clinical trials for diabetic foot ulcers.
-
RESEARCH TRIANGLE PARK, N.C, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics, a regenerative medicine company developing biologically derived therapeutics, announced the enrollment of the...
-
FDA approves Discovery Therapeutic Caribe's Phase 3 trial for intralesional rhEGF in severe diabetic foot ulcers.